Nancy E Kemeny Selected Research

Floxuridine (FUdR)

1/2022	Genomic Stratification of Resectable Colorectal Liver Metastasis Patients and Implications for Adjuvant Therapy and Survival.
1/2021	A Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Therapy With or Without Panitumumab After Hepatic Resection of KRAS Wild-type Colorectal Cancer.
1/2020	Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
2/2013	Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a 1 H MRS study.
5/2012	Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors.
12/2011	Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer.
1/2011	Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?
7/2009	Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma.
5/2009	The role of floxuridine in metastatic liver disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nancy E Kemeny Research Topics

Disease

68	Neoplasm Metastasis (Metastasis) 11/2022 - 12/2002
55	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 01/2003
45	Neoplasms (Cancer) 03/2022 - 12/2002
7	Colonic Neoplasms (Colon Cancer) 03/2022 - 04/2003
5	Cholangiocarcinoma 01/2020 - 01/2011
5	Liver Diseases (Liver Disease) 11/2019 - 05/2009
3	Sclerosis 05/2012 - 04/2002
2	Infections 03/2022 - 12/2019
2	Hypersensitivity (Allergy) 01/2022 - 01/2016
2	Fibrosis (Cirrhosis) 01/2020 - 09/2012
2	Hepatocellular Carcinoma (Hepatoma) 10/2019 - 01/2011
2	Exanthema (Rash) 01/2017 - 12/2007
2	Necrosis 12/2012 - 09/2012
2	Rectal Neoplasms (Rectal Cancer) 11/2012 - 12/2002
1	Carcinoma (Carcinomatosis) 03/2022
1	Hypertrophy 01/2022
1	Margins of Excision 01/2022
1	Breast Neoplasms (Breast Cancer) 01/2021
1	Non-alcoholic Fatty Liver Disease 01/2020
1	Blood Vessel Dissection 12/2019
1	Thrombosis (Thrombus) 12/2019
1	Hematoma 12/2019
1	Hemorrhage 12/2019
1	Thrombocytopenia (Thrombopenia) 11/2019
1	Spinal Cord Compression 01/2018
1	Spontaneous Fractures (Pathological Fracture) 01/2018
1	Sarcoma (Soft Tissue Sarcoma) 03/2017
1	Hyperbilirubinemia 02/2014
1	Acinar Cell Carcinoma 03/2013
1	Disease Progression 03/2013
1	Pathologic Constriction (Stenosis) 05/2012
1	Small Cell Carcinoma 12/2011
1	Adenocarcinoma 08/2011
1	Wounds and Injuries (Trauma) 03/2011
1	Nasal Septal Perforation 03/2011

Drug/Important Bio-Agent (IBA)

9	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022 - 08/2003
9	Floxuridine (FUdR)FDA LinkGeneric 01/2022 - 05/2009
9	Irinotecan (Camptosar)FDA LinkGeneric 01/2021 - 04/2003
8	Pharmaceutical PreparationsIBA 11/2021 - 09/2005
8	Fluorouracil (Carac)FDA LinkGeneric 01/2021 - 04/2003
7	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2012
7	Carcinoembryonic AntigenIBA 01/2020 - 03/2014
7	Bevacizumab (Avastin)FDA Link 09/2012 - 10/2007
4	Leucovorin (Folinic Acid)FDA Link 01/2021 - 04/2003
4	Cetuximab (Erbitux)FDA Link 01/2017 - 03/2005
4	Monoclonal AntibodiesIBA 10/2015 - 04/2003
4	Dexamethasone (Maxidex)FDA LinkGeneric 01/2011 - 04/2002
3	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 04/2004
3	Yttrium-90IBA 12/2015 - 01/2014
3	AntigensIBA 10/2015 - 08/2011
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2021
2	BilirubinIBA 01/2014 - 03/2006
2	AntibodiesIBA 12/2011 - 06/2010
2	ErbB Receptors (EGF Receptor)IBA 06/2010 - 03/2005
2	Thymidylate SynthaseIBA 03/2006 - 04/2004
1	Ethiodized Oil (Ethiodol)FDA Link 11/2021
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 11/2021
1	Epithelial Cell Adhesion MoleculeIBA 01/2021
1	Panitumumab (Vectibix)FDA Link 01/2021
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2021
1	Cyclin-Dependent Kinase Inhibitor p16IBA 01/2021
1	Gemcitabine FDA Link 01/2020
1	nasIBA 01/2020
1	serum P-component (CIt)IBA 11/2019
1	romiplostim FDA Link 11/2019
1	Circulating Tumor DNAIBA 06/2019
1	APTIBA 01/2018
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 03/2017
1	Dapsone FDA Link 01/2017
1	Capecitabine (Xeloda)FDA Link 01/2016
1	Neoplasm Antigens (Tumor Antigens)IBA 10/2015
1	GadoliniumIBA 08/2014
1	SirtuinsIBA 03/2014
1	LipidsIBA 02/2013
1	Caspase 3 (Caspase-3)IBA 12/2012
1	Mucin-6IBA 09/2012
1	MucinsIBA 09/2012
1	P-30 composite resin (P 30)IBA 09/2012
1	PlatinumIBA 12/2011
1	Radioisotopes (Radionuclides)IBA 12/2011
1	Etoposide (VP 16)FDA LinkGeneric 12/2011
1	EdrecolomabIBA 08/2011

Therapy/Procedure

66	Drug Therapy (Chemotherapy) 11/2022 - 12/2002
27	Therapeutics 01/2022 - 12/2002
10	Infusion Pumps (Infusion Pump) 03/2022 - 05/2012
10	Hepatectomy 01/2021 - 03/2008
7	Radiofrequency Ablation 01/2022 - 06/2011
6	Radiotherapy 10/2019 - 12/2002
6	Salvage Therapy 12/2015 - 08/2003
4	Microspheres (Microsphere) 11/2021 - 01/2014
4	Adjuvant Chemotherapy 01/2021 - 07/2009
4	Stents 02/2014 - 07/2009
4	Combination Drug Therapy (Combination Chemotherapy) 07/2009 - 04/2003
3	Neoadjuvant Therapy 06/2008 - 03/2005
2	Metastasectomy 01/2020 - 08/2014
2	Palliative Care (Palliative Therapy) 12/2012 - 07/2009
1	Colectomy 03/2022
1	Radiofrequency Therapy 01/2017
1	Electrodes (Electrode) 12/2012
1	Radioimmunotherapy 12/2011